AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Rocket Pharmaceuticals CFO Aaron Ondrey Steps Down to Pursue New Opportunities
ByAinvest
Tuesday, Aug 26, 2025 1:13 am ET1min read
Rocket Pharmaceuticals' CFO Aaron Ondrey resigned on August 20, 2025, to pursue other opportunities, with his last day being September 5, 2025. Martin Wilson, the company's General Counsel and Chief Corporate Officer, was appointed interim Principal Financial Officer on August 25, 2025, effective September 8, 2025.
Rocket Pharmaceuticals (RCKT) announced the resignation of its Chief Financial Officer (CFO), Aaron Ondrey, effective September 5, 2025. Ondrey will pursue other opportunities, as per a regulatory filing [1]. Martin Wilson, the company's General Counsel and Chief Corporate Officer, has been appointed as the interim Principal Financial Officer (PFO), effective September 8, 2025 [1].Ondrey joined Rocket Pharmaceuticals in March 2024 and served as the CFO until his resignation. His total compensation for 2024 was approximately $3 million [3]. Wilson, who joined the company as General Counsel and Chief Compliance Officer in November 2021 and became Chief Corporate Officer in March 2024, will take over the interim PFO role [3].
The resignation of Ondrey comes amidst significant developments for Rocket Pharmaceuticals. The company's pivotal Phase 2 trial of RP-A501 for Danon disease had a clinical hold lifted by the FDA in late July 2025 [2]. The FDA's decision to resume the trial, following a recalibrated dose and revised protocol, is a positive development for the company and its stock [2].
Rocket Pharmaceuticals' stock, RCKT, saw a 33.68% increase during the premarket session on Wednesday, August 25, 2025, following the FDA's decision [2]. The stock was trading at $3.91 at the time, indicating investor confidence in the company's progress.
The changes in Rocket Pharmaceuticals' leadership and the FDA's decision on the pivotal trial are significant developments for the company. Investors should closely monitor these developments for potential impacts on the company's financial performance and stock price.
References:
[1] https://www.tipranks.com/news/the-fly/rocket-pharmaceuticals-cfo-aaron-ondrey-resigns-to-pursue-other-opportunities-thefly
[2] https://www.benzinga.com/news/fda/25/08/47233429/fda-lifts-rocket-pharmaceuticals-study-hold-for-rare-disease-gene-therapy
[3] https://www.marketwatch.com/story/rocket-pharmaceuticals-cfo-aaron-ondrey-resigns-0a7dd960
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet